Articles

• A perspective on sporadic inclusion-body myositisThe role of aging and inflammatory processes

  Caleb E. Finch

  • Abstract
  • Full Text
  • Full Text (PDF)
• The ubiquitin proteolytic systemFrom a vague idea, through basic mechanisms, and onto human diseases and drug targeting

  Aaron Ciechanover

  • Full Text
  • Full Text (PDF)
• Inclusion-body myositisClinical, diagnostic, and pathologic aspects

  W. King Engel, Valerie Askanas

  • Abstract
  • Full Text
  • Full Text (PDF)
• The current status of treatment for inclusion-body myositis

  Robert C. Griggs

  • Abstract
  • Full Text
  • Full Text (PDF)
• Inflammatory, immune, and viral aspects of inclusion-body myositis

  Marinos C. Dalakas

  • Abstract
  • Full Text
  • Full Text (PDF)
• Inclusion-body myositisA myodegenerative conformational disorder associated with Aβ, protein misfolding, and proteasome inhibition

  Valerie Askanas, W. King Engel

  • Abstract
  • Full Text
  • Full Text (PDF)
• Mitochondrial abnormalities in inclusion-body myositis

  A. Oldfors, A. R. Moslemi, L. Jonasson, M. Ohlsson, G. Kollberg, C. Lindberg

  • Abstract
  • Full Text
  • Full Text (PDF)
• Controlling autoimmunity in sporadic inclusion-body myositis

  Lawrence Steinman

  • Full Text
  • Full Text (PDF)
• Immunotherapeutic relief from persistent infections and amyloid disorders

  Dorian B. McGavern

  • Abstract
  • Full Text
  • Full Text (PDF)
• Inclusion-body myositis and Alzheimer diseaseTwo sides of the same coin, or different currencies altogether?

  M. Paul Murphy, Todd E. Golde

  • Full Text
  • Full Text (PDF)
• Amyloidogenic processing of β-amyloid precursor protein in intracellular compartments

  Kulandaivelu S. Vetrivel, Gopal Thinakaran

  • Abstract
  • Full Text
  • Full Text (PDF)
• Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis

  Charles G. Glabe, Rakez Kayed

  • Abstract
  • Full Text
  • Full Text (PDF)
• Apolipoprotein E and Alzheimer disease

  Yadong Huang

  • Abstract
  • Full Text
  • Full Text (PDF)
• Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies

  F. W. van Leeuwen, P. van Tijn, M.A.F. Sonnemans, B. Hobo, D. M.A. Mann, C. Van Broeckhoven, S. Kumar-Singh, P. Cras, G. Leuba, A. Savioz, M. L.C. Maat-Schieman, H. Yamaguchi, J. M. Kros, W. Kamphorst, E. M. Hol, R. A.I. de Vos, D. F. Fischer

  • Abstract
  • Full Text
  • Full Text (PDF)
• Preferential degradation of oxidized proteins by the 20S proteasome may be inhibited in aging and in inflammatory neuromuscular diseases

  Kelvin J.A. Davies, Reshma Shringarpure

  • Abstract
  • Full Text
  • Full Text (PDF)
• Brain and brawnParallels in oxidative strength

  P. I. Moreira, K. Honda, X. Zhu, A. Nunomura, G. Casadesus, M. A. Smith, G. Perry

  • Abstract
  • Full Text
  • Full Text (PDF)
• The unfolded protein responseA stress signaling pathway critical for health and disease

  Kezhong Zhang, Randal J. Kaufman

  • Abstract
  • Full Text
  • Full Text (PDF)
• Treatment and prevention of the amyloidosesCan the lessons learned be applied to sporadic inclusion-body myositis?

  Joel N. Buxbaum

  • Abstract
  • Full Text
  • Full Text (PDF)
• RNA interference as potential therapy for neurodegenerative diseaseApplications to inclusion-body myositis?

  Henry Paulson

  • Abstract
  • Full Text
  • Full Text (PDF)
• Developing therapeutics for the diseases of protein misfolding

  Barnaby C.H. May, Cedric Govaerts, Fred E. Cohen

  • Abstract
  • Full Text
  • Full Text (PDF)
• Pilot trial of etanercept in the treatment of inclusion-body myositis

  R. J. Barohn, L. Herbelin, J. T. Kissel, W. King, A. L. McVey, D. S. Saperstein, J. R. Mendell

  • Abstract
  • Full Text
  • Full Text (PDF)